Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
The results will be analyzed based on whether or not participants have a mutation in the Enhancer of zeste homolog 2 (EZH2) gene (known as EZH2 wild-type).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults aged 18 years or older
Histologically confirmed follicular lymphoma grades 1, 2, or 3A
At least two prior lines of systemic therapy
Prescribed tazemetostat according to United States prescribing information (USPI)
Known or planned EZH2 mutation status
Signed informed consent
You may not be if
Grade 3B or transformed follicular lymphoma
Other hematologic malignancies
Use of strong/moderate Cytochrome P450 (CYP3A) inhibitors
